Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A

被引:16
作者
Murakami, Yuichi
Tanaka, Tomoaki
Murakami, Hideyasu
Tsujimoto, Masayuki
Ohtani, Hisakazu
Sawada, Yasufumi
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Drug Informat, Bunkyo Ku, Tokyo 1130033, Japan
[2] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Medico Pharmaceut Sci, Higashi Ku, Fukuoka 8128582, Japan
关键词
ciclosporin A; dosage; drug interaction; pharmacokinetic model; St John's wort;
D O I
10.1111/j.1365-2125.2006.02606.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims St John's wort (SJW) decreases the blood concentration of ciclosporin A (CsA), which may result in allograft rejection. In addition, the time course of this interaction is not parallel with the administration of SJW. We aimed to develop a pharmacokinetic model to predict the time profile of blood CsA concentrations during and after the intake of SJW. Methods We developed a pharmacokinetic model incorporating turnover of detoxicating proteins, with the assumption that the amount of detoxicating proteins is in inverse proportion to the ratio of trough blood concentration to daily dose (C/D ratio) of CsA. First, we collected time profiles of blood CsA during and after the intake of SJW from the literature. Next, we analysed the relationship between D/C ratio and the daily dose of SJW at steady state. Subsequently, the developed model was simultaneously fitted to the time profiles of C/D ratios by using a nonlinear least-squares method to obtain model parameters. Results The model analysis revealed that the induction of the detoxicating proteins by SJW was saturable with an elimination rate constant of the detoxicating proteins (k(e)) of 4.72 month(-1). Elimination half-life of the detoxicating proteins calculated from the k(e) value was 4.4 days, suggesting that the dose of CsA should be carefully monitored for up to 2 weeks after the cessation of SJW intake. Conclusions The present model may provide additional information for use in identifying optimal dosage regimens of CsA during and after the intake of SJW to prevent an adverse drug interaction between CsA and SJW.
引用
收藏
页码:671 / 676
页数:6
相关论文
共 15 条
[1]   Herbal supplements: A potential for drug interactions in transplant recipients [J].
Barone, GW ;
Gurley, BJ ;
Ketel, BL ;
Abul-Ezz, SR .
TRANSPLANTATION, 2001, 71 (02) :239-241
[2]   Drug interaction between St. John's wort and cyclosporine [J].
Barone, GW ;
Gurley, BJ ;
Ketel, BL ;
Lightfoot, ML ;
Abul-Ezz, SR .
ANNALS OF PHARMACOTHERAPY, 2000, 34 (09) :1013-1016
[3]   Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients [J].
Bauer, S ;
Störmer, E ;
Johne, A ;
Krüger, H ;
Budde, K ;
Neumayer, HH ;
Roots, I ;
Mai, I .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (02) :203-211
[4]  
Beer AM, 2001, MED KLIN, V96, P480, DOI 10.1007/PL00002231
[5]   Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum) [J].
Breidenbach, T ;
Kliem, V ;
Burg, M ;
Radermacher, J ;
Hoffmann, MW ;
Klempnauer, J .
TRANSPLANTATION, 2000, 69 (10) :2229-2230
[6]   COMPARISON OF 4 BASIC MODELS OF INDIRECT PHARMACODYNAMIC RESPONSES [J].
DAYNEKA, NL ;
GARG, V ;
JUSKO, WJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1993, 21 (04) :457-478
[7]   Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation [J].
Karliova, M ;
Treichel, U ;
Malagò, M ;
Frilling, A ;
Gerken, G ;
Broelsch, CE .
JOURNAL OF HEPATOLOGY, 2000, 33 (05) :853-855
[8]   St John's wort for depression - An overview and meta-analysis of randomised clinical trials [J].
Linde, K ;
Ramirez, G ;
Mulrow, CD ;
Pauls, A ;
Weidenhammer, W ;
Melchart, D .
BRITISH MEDICAL JOURNAL, 1996, 313 (7052) :253-258
[9]  
Mai I, 2000, INT J CLIN PHARM TH, V38, P500
[10]   Undeclared exposure to St. John's Wort in hospitalized patients [J].
Martin-Facklam, M ;
Rieger, K ;
Riedel, KD ;
Burhenne, J ;
Walter-Sack, I ;
Haefeli, WE .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (04) :437-441